Tag: Glutamate release inhibitor / sodium channel blocker

  • Riluzole

    Glutamate release inhibitor / sodium channel blocker

    A benzothiazole glutamate release inhibitor with sodium channel block; the first FDA-approved drug for amyotrophic lateral sclerosis.

    Abstract

    Riluzole (6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; CAS 1744-22-5; molecular formula C8H5F3N2OS; molecular weight 234.20) is a benzothiazole compound developed at Rhone-Poulenc and approved by the FDA in 1995 (Rilutek) for amyotrophic lateral sclerosis. The compound was the first ALS-approved drug and remained the only one until edaravone in 2017. Mechanism is multifactorial: state-dependent voltage-gated sodium channel inhibition (reducing glutamate release from presynaptic terminals), AMPA and kainate receptor antagonism (postsynaptic glutamate effect), and modest GABA-A potentiation. The combined glutamate-reducing activity addresses the excitotoxicity hypothesis of ALS pathogenesis. Plasma half-life is approximately 12 hours; metabolism is via CYP1A2. The clinical effect in ALS is modest (median survival extension approximately 2 to 3 months) but consistent across trials. Off-label use in major depressive disorder (where ketamine’s NMDA mechanism inspired interest in glutamate modulators), generalized anxiety disorder, and OCD has been investigated. Used as the canonical glutamate release inhibitor in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.